S. ŞIVGIN, "Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): a randomised, open-label, phase 3b study," LANCET ONCOLOGY , vol.2045, no.16, pp.30558-30567, 2016
ŞIVGIN, S. 2016. Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): a randomised, open-label, phase 3b study. LANCET ONCOLOGY , vol.2045, no.16 , 30558-30567.
ŞIVGIN, S., (2016). Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): a randomised, open-label, phase 3b study. LANCET ONCOLOGY , vol.2045, no.16, 30558-30567.
ŞIVGIN, Serdar. "Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): a randomised, open-label, phase 3b study," LANCET ONCOLOGY , vol.2045, no.16, 30558-30567, 2016
ŞIVGIN, Serdar. "Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): a randomised, open-label, phase 3b study." LANCET ONCOLOGY , vol.2045, no.16, pp.30558-30567, 2016
ŞIVGIN, S. (2016) . "Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): a randomised, open-label, phase 3b study." LANCET ONCOLOGY , vol.2045, no.16, pp.30558-30567.
@article{article, author={Serdar ŞIVGIN}, title={Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): a randomised, open-label, phase 3b study}, journal={LANCET ONCOLOGY}, year=2016, pages={30558-30567} }